The study, published in Annals of Gastroenterological Surgery, assembled clinical data from 18 Japanese medical institutions, most of them high-volume board-certified training centers, covering patients who underwent initial curative-intent liver resection between January 2006 and December 2016. Of 1251 patients initially screened, 584 met the strict inclusion criteria, which required a known KRAS mutation profile, complete follow-up data, and exclusion of palliative R2 resections and BRAF-mutant tumors. The cohort was predominantly male with a median age of 66 years, and about a quarter of patients had right-sided primary colorectal tumors. Nearly two-thirds had nodal metastases from the primary tumor, almost 70 percent presented with synchronous liver metastases, and during a median follow-up of 44.1 months, a striking 79.1 percent of patients developed tumor recurrence—figures that underscore the aggressive nature of this disease even after apparently curative surgery.

At the heart of the investigation lies the KRAS oncogene, whose mutational status has become indispensable for designing treatment strategies in the era of targeted molecular therapy. Using Sanger sequencing of codons 12 and 13 on formalin-fixed paraffin-embedded tissue, the researchers detected KRAS mutations in 36.8 percent of patients. Mutant tumors were significantly more common in right-sided colon cancers, echoing the well-established embryological and molecular divide between the midgut-derived right colon and the hindgut-derived left colon and rectum. Critically, the survival analysis revealed that KRAS mutation was associated with both shorter recurrence-free survival and shorter overall survival across the entire cohort: median overall survival was 47.3 months for mutant carriers versus 70.6 months for wild-type patients, with five-year survival of 36.8 percent versus 55.6 percent respectively.

Yet the most provocative finding concerned geography within the colon itself. When the analysis was stratified by primary tumor sidedness, the prognostic power of KRAS mutation vanished on the right side and intensified on the left. Among patients with left-sided primaries, KRAS mutation conferred significantly worse overall and recurrence-free survival, with median overall survival of 44.2 months versus 69.4 months for wild-type disease. Among right-sided patients, by contrast, survival curves for mutant and wild-type tumors were statistically indistinguishable. This asymmetry suggests that the biological pathways driving metastatic behavior differ fundamentally according to embryological origin, and it cautions against treating KRAS as a universal prognostic marker. It also raises the possibility that right-sided disease harbors other, still unidentified molecular determinants—such as BRAF mutations or microsatellite instability—that may dominate its clinical course.

The second pillar of the study is the tumor burden score, or TBS, an elegant geometric construct that captures the cumulative impact of tumor size and number on a single continuous scale. Each patient is assigned coordinates on a Cartesian plane according to maximum tumor diameter and lesion count, and the Pythagorean distance from the origin yields the score. In this cohort, TBS grading stratified overall survival more powerfully than tumor size or number alone. But here, too, the interplay with genetics proved decisive: among KRAS wild-type patients, TBS grades separated median survival from 87.1 months in the low-burden group down to 43.8 months in the high-burden group, whereas among KRAS-mutant patients the survival curves collapsed into statistical sameness. In other words, a KRAS mutation appeared to define prognosis entirely independently of the anatomical burden of liver disease—a finding with profound implications for how tumor biology and tumor morphology should be weighed against each other.

Multivariate Cox regression distilled five independent preoperative predictors of survival: primary tumor nodal metastasis, KRAS mutation, extrahepatic disease, high tumor burden score, and elevated CA19-9 above 40 units per milliliter. Notably, CEA—the traditional tumor marker of colorectal cancer—did not survive multivariate adjustment, whereas CA19-9 did, a choice consistent with recent CRLM-specific studies that have demonstrated the prognostic relevance of CA19-9 even in patients receiving preoperative chemotherapy. These five variables were then integrated into a graphical nomogram that assigns weighted points to each factor and converts the summed total into predicted three- and five-year survival probabilities. Unlike categorical scoring systems, the nomogram preserves the relative weighting of individual risk factors and yields a continuous estimate of biological risk at the moment of diagnosis.

The performance data are compelling. When the cohort was divided into low-, medium-, and high-risk groups by total nomogram points, median overall survival separated cleanly into 95.6, 66.0, and 40.4 months respectively, with five-year survival spanning from 73.1 percent in the low-risk group to just 27.9 percent in the high-risk group. The same framework stratified recurrence-free survival with equal consistency, and—crucially—it predicted the pattern of relapse. Higher biological risk was associated with a growing proportion of extrahepatic recurrence involving lung, lymph nodes, and peritoneum, a signature of systemic metastatic propensity rather than merely local liver disease. Measured by Harrell’s C-index, the new model outperformed both the classic Fong clinical risk score of 1999 (0.627 versus 0.553) and the MD Anderson modified clinical risk score (0.627 versus 0.581), with lower Akaike information criterion values confirming superior fit. Internal validation through 1000 bootstrap resamples demonstrated an optimism-corrected C-index of 0.636 and a calibration slope of 0.931, indicating minimal overfitting and good agreement between predicted and observed survival.

It is this recurrence-pattern insight that breathes life into the concept of biological resectability. Even when a tumor is technically resectable by radiological criteria, a high nomogram score signals a hidden risk of systemic spread that surgery alone cannot address. In the high-risk group, roughly 90 percent of patients relapsed after hepatectomy, and in the low- and medium-risk groups recurrence was comparable, suggesting these groups differ qualitatively from high-risk disease in the degree of systemic cancer dissemination. The authors therefore propose distinguishing patients who technically qualify for resection but carry high biological risk as biologically borderline resectable—a category in which hepatic resection may be only one component of multimodal therapy rather than an optimally curative option. Importantly, the framework is presented as hypothesis-generating and complementary to anatomical assessment, not as a validated treatment algorithm, and it requires prospective validation in predominantly technically resectable cohorts.

The study is not without limitations, which the authors address with candor. The nomogram was developed and evaluated within the same multicenter Japanese cohort, so external validation in international populations remains essential. Because KRAS testing was not routine early in the study period, 649 patients with unknown mutation status were excluded, potentially introducing selection bias toward a more contemporary molecularly characterized population. Paired molecular analyses of primary tumors and metastases were unavailable, leaving open the question of KRAS discordance, and extended RAS and co-alteration analyses involving TP53, SMAD4, and other genes were not systematically performed. Dynamic changes in tumor morphology and marker levels during preoperative chemotherapy were likewise not incorporated. The risk-group cutoffs are explicitly exploratory, intended to facilitate interpretation rather than to define fixed biological categories.

Nevertheless, the implications for clinical practice are substantial. The nomogram demonstrates that resectability should be conceived along a continuous biological spectrum rather than as a binary yes-or-no verdict, and it provides an objective, readily computable instrument to locate any individual patient on that spectrum. By fusing molecular information—KRAS status—with geometric tumor burden, nodal status, extrahepatic disease, and CA19-9, the model captures dimensions of metastatic behavior that traditional scores built in the chemotherapy era of the 1990s cannot. Preclinical evidence suggesting that oncogenic Ras signaling cooperates with TP53 loss to promote invasion and systemic spread lends mechanistic plausibility to the observed link between high biological risk and extrahepatic recurrence. As molecular profiling becomes universal in colorectal cancer care, tools of this kind could reshape multidisciplinary decision-making, ensuring that the question asked before liver surgery is no longer only whether the tumor can be removed, but whether removing it will truly serve the patient.

Subject of Research: A nomogram-based continuous biological risk model for defining biologically borderline resectable colorectal liver metastases based on KRAS status and tumor burden.

Article Title: Biological Resectability in Colorectal Liver Metastases: A Nomogram‐Based Continuous Risk Model to Define Borderline Disease

Article References: Umeda, Y., Mitsuhashi, T., Fuji, T., Kojima, T., Koujima, T., Matsuda, T., Satoh, D., Inagaki, M., Takagi, K., & Fujiwara, T. (2026). Biological Resectability in Colorectal Liver Metastases: A Nomogram‐Based Continuous Risk Model to Define Borderline Disease. Annals of Gastroenterological Surgery, Article ags3.70278. https://doi.org/10.1002/ags3.70278

Image Credits: AI Generated

DOI: 10.1002/ags3.70278

Keywords: colorectal liver metastases, KRAS mutation, nomogram, tumor burden score, biological resectability, hepatectomy, CA19-9, overall survival, recurrence-free survival, borderline resectable, prognostic model, colorectal cancer

The retrospective cohort study analyzed data from 195 colorectal cancer patients who underwent curative surgery following neoadjuvant immune checkpoint inhibitor therapy. The researchers, led by Bo Liu and Bo Li with corresponding authors Jinzhu Zhang, Xueqiang Jian and Zhanlun Liu, examined the relationship between lymph node yield, the total number of lymph nodes retrieved and examined by the pathologist after surgery, and postoperative recurrence. Their central finding was striking: patients with a lymph node yield of twenty or more nodes had significantly poorer recurrence-free survival than patients with lower yields. This association persisted across subgroup analyses stratified by pathological tumor stage, microsatellite status, the type of immune checkpoint inhibitor used, and the neoadjuvant treatment strategy, indicating that the signal was not confined to a narrow slice of the patient population.

To understand why this finding matters, it helps to consider the biology of tumor-draining lymph nodes. These are the lymph nodes that receive drainage from the tumor site, and they are far more than passive filters. They are active immunological hubs where dendritic cells present tumor antigens to naive T cells, where anti-tumor immune responses are primed, and where the immune system mounts its organized defense against cancer. Immune checkpoint inhibitors, drugs that unleash T cells by blocking inhibitory receptors such as PD-1, depend heavily on this lymph node machinery. In many cancers, the response to checkpoint blockade is initiated in the tumor-draining lymph nodes, where T cells are activated and then traffic to the tumor to do their work. Removing these nodes, therefore, might not be an immunologically neutral act.

The study’s single-cell analysis adds a fascinating layer to the story. The researchers performed single-cell RNA sequencing and T-cell receptor sequencing on tumor tissue, peripheral blood, and tumor-draining lymph node samples from colorectal cancer patients. This allowed them to track individual immune cells and, crucially, to identify which T cells in the tumor were clonally related to T cells in the lymph nodes, meaning they shared identical T-cell receptor sequences and therefore descended from the same activated precursor cells. What they found was that patients treated with immune checkpoint inhibitors exhibited a higher frequency of clonally shared CD8-positive effector memory T cells between the tumor-draining lymph nodes and the tumor tissue itself.

This clonal sharing is direct evidence of immunological connectivity between the lymph nodes and the tumor. It suggests that T cells activated in the tumor-draining lymph nodes, under the stimulus of checkpoint blockade, are physically migrating to the tumor and participating in the anti-cancer attack. In other words, the lymph nodes are not just staging grounds for the immune response; they are functioning as the factories that produce the tumor-fighting T cell army that immunotherapy mobilizes. When surgeons remove twenty or more of these nodes, they may be inadvertently dismantling a critical component of the patient’s own anti-tumor immune infrastructure at precisely the moment when immunotherapy has primed it for action.

The clinical implications are potentially significant, though the researchers are careful to note the limits of what their study can establish. As a retrospective cohort study, it demonstrates association rather than causation. It is possible that higher lymph node yield is a marker of more extensive disease or more aggressive surgical practice rather than a direct cause of recurrence. Patients with more nodes removed may have had more advanced disease that prompted wider dissections, or surgeons who remove more nodes may differ systematically in ways that affect outcomes. The authors themselves acknowledge that the mechanisms underlying the association remain unclear and warrant further investigation. Nevertheless, the consistency of the finding across multiple subgroup analyses, and its alignment with a plausible biological mechanism supported by the single-cell data, gives the result a credibility that demands attention.

The finding also sits within a broader and sometimes contentious debate in surgical oncology about the optimal extent of lymphadenectomy. In colorectal cancer, guidelines typically recommend examining at least twelve lymph nodes to ensure accurate staging, since understaging can lead to inadequate adjuvant treatment decisions. Lymph node yield has historically been used as a quality metric for both surgery and pathology, with higher yields generally interpreted as evidence of more thorough cancer care. The new study does not necessarily overturn that logic for patients who do not receive neoadjuvant immunotherapy, but it raises the provocative possibility that the optimal surgical strategy may differ depending on whether a patient’s immune system has been pharmacologically primed before the operation.

Neoadjuvant immunotherapy itself is a rapidly expanding approach in colorectal cancer, particularly for patients with mismatch repair-deficient or microsatellite instability-high tumors, which are exquisitely sensitive to checkpoint blockade. In these patients, preoperative immunotherapy can produce pathological complete responses, allowing some to avoid radical surgery altogether. As the use of neoadjuvant immunotherapy grows, questions about how to adapt standard surgical techniques become increasingly urgent. If tumor-draining lymph nodes are essential partners in the immunotherapy response, as this study’s single-cell data suggest, then the standard practice of extensive lymph node dissection may need to be re-evaluated in this specific patient population, balancing the staging benefits of node removal against the potential immunological cost.

The study also highlights the power of single-cell technologies to illuminate questions that traditional pathology cannot answer. By combining T-cell receptor sequencing across multiple tissue compartments, the researchers were able to visualize the traffic of immune cells between lymph nodes and tumors in a way that would have been impossible a decade ago. This kind of integrative analysis, linking clinical outcomes with high-resolution immune profiling, represents a model for how surgical oncology questions may be addressed in the future. Rather than asking simply how many nodes to remove, surgeons and oncologists may increasingly ask what immunological functions those nodes are performing and how to preserve them.

For now, the study’s authors urge caution rather than immediate changes to practice. The association between higher lymph node yield and poorer recurrence-free survival in immunotherapy-treated colorectal cancer patients is a hypothesis-generating finding, one that should prompt prospective studies designed to test whether more conservative lymph node management could safely improve outcomes. If those studies confirm the retrospective signal, the implications would extend beyond colorectal cancer to any malignancy treated with neoadjuvant immunotherapy and surgery. What is clear already is that the era of immunotherapy is forcing a re-examination of long-held surgical dogmas, and the humble lymph node, once viewed merely as a structure to be counted and cleared, is emerging as an active and potentially indispensable ally in the fight against cancer.

Subject of Research: The association between lymph node yield and recurrence-free survival in colorectal cancer patients treated with neoadjuvant immune checkpoint inhibitor therapy

Article Title: Higher lymph node yield is associated with increased postoperative recurrence in colorectal cancer treated with neoadjuvant immunotherapy: a retrospective cohort study

Article References: Liu, B., Li, B., Zhang, J., Jian, X., & Liu, Z. (2026). Higher lymph node yield is associated with increased postoperative recurrence in colorectal cancer treated with neoadjuvant immunotherapy: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16966-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16966-4

Keywords: colorectal cancer, immune checkpoint inhibitors, neoadjuvant immunotherapy, tumor-draining lymph nodes, lymph node yield, recurrence-free survival, single-cell RNA sequencing, T-cell receptor sequencing, CD8 T cells, lymphadenectomy, surgical oncology, tumor immunology

Colorectal cancer remains one of the most common malignancies worldwide, and while radical surgery is highly effective when the disease has not spread to distant organs, stage III disease, defined by lymph node involvement, carries a recurrence rate of 20 to 30 percent. Adjuvant chemotherapy after surgery has been proven in randomized controlled trials to reduce this risk and improve survival. However, the picture becomes murkier in patients aged 70 and older. As people age, comorbidities accumulate and organ function declines, making chemotherapy harder to tolerate and raising the risk of serious adverse events. Notably, there is no consistent evidence that adding oxaliplatin provides additional benefit in this age group, suggesting that the therapeutic effect of adjuvant chemotherapy may be limited for many elderly patients.

This uncertainty creates a real clinical dilemma. Physicians must weigh the possibility of a survival benefit against the substantial burden chemotherapy can impose on an older body. The Japanese research team, led by Tomoya Tago and Yasuyuki Takamizawa, set out to determine whether simple blood-derived markers, calculated from tests already ordered in routine care, could identify which elderly patients are most likely to benefit from postoperative chemotherapy and which might safely avoid it.

The study included patients aged 70 or older who underwent radical resection of pathologically confirmed stage III colorectal adenocarcinoma at the National Cancer Center Hospital between January 2000 and December 2017. After excluding those with other primary cancers, prior neoadjuvant therapy, or incomplete data, 308 patients remained, of whom 177 received adjuvant chemotherapy and 131 did not. Because patients selected for chemotherapy were significantly younger and likely healthier than those who were not, the researchers used propensity score matching to balance the two groups on sex, age, body mass index, comorbidities, tumor location and stage, histology, and preoperative tumor marker levels. This produced 78 matched pairs with well-balanced baseline characteristics.

The survival benefit of adjuvant chemotherapy held up after matching. The five-year recurrence-free survival rate was 76.6 percent in the chemotherapy group versus 62.8 percent in the non-treatment group, with a hazard ratio of 0.537. Five-year overall survival was 84.1 percent versus 73.9 percent, with a hazard ratio of 0.495. Both differences were statistically significant, confirming that adjuvant chemotherapy remains worthwhile for properly selected elderly patients overall.

The most striking findings emerged when the researchers stratified the matched cohort by nine preoperative and postoperative immuno-nutritional and inflammatory markers, including the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index, geriatric nutritional risk index, controlling nutritional status score, Glasgow Prognostic Score, and modified Glasgow Prognostic Score. Two postoperative markers showed significant interactions with chemotherapy benefit: the lymphocyte-to-monocyte ratio and the C-reactive protein-to-albumin ratio.

In patients with a high postoperative LMR, defined by the study’s cut-off of 5.27, adjuvant chemotherapy produced a dramatic improvement. Five-year recurrence-free survival reached 84.4 percent in the treated group versus just 53.0 percent in the untreated group, a hazard ratio of 0.27. Overall survival showed an even starker contrast: 92.1 percent versus 68.0 percent, with a hazard ratio of 0.16. Yet in patients with a low postoperative LMR, chemotherapy provided essentially no advantage, with five-year recurrence-free survival of 69.2 percent versus 72.9 percent, and overall survival of 76.9 percent versus 80.4 percent, both comparisons statistically indistinguishable.

The CAR told a similar story. Patients with a high postoperative CAR, above the cut-off of 0.026, derived marked benefit from chemotherapy, with five-year recurrence-free survival of 79.0 percent versus 47.8 percent and overall survival of 88.0 percent versus 62.4 percent. In those with a low CAR, the survival curves of treated and untreated patients were nearly superimposable. The biological rationale is rooted in tumor-host interactions: lymphocytes mount anti-tumor immune responses and their preservation is associated with better drug responsiveness, whereas systemic inflammation, marked by elevated C-reactive protein relative to albumin, reflects a cytokine-driven state regulated by interleukin-1, interleukin-6, and tumor necrosis factor-alpha that generally portends poorer outcomes. Because postoperative samples in this study were collected uniformly four to eight weeks after surgery, once acute inflammatory responses from the operation had subsided, the markers likely captured the patient’s intrinsic baseline immunity at the moment chemotherapy would begin, rather than residual tumor-driven inflammation.

The clinical appeal of these markers lies in their simplicity and cost. Unlike circulating tumor DNA, which shows promise for predicting treatment efficacy but remains expensive and not yet widely implementable, LMR and CAR can be calculated from standard complete blood counts and chemistry panels already obtained in routine follow-up. The authors suggest that these values could serve as supplementary information alongside age, performance status, and comorbidities when the indication for adjuvant chemotherapy is being considered, helping individualize decisions rather than uniformly determine them.

The researchers acknowledge important limitations. The study was retrospective and single-center, so selection bias and institution-specific treatment practices cannot be fully excluded, and the derived cut-off values may not generalize elsewhere. Standardized comorbidity assessment tools such as the Charlson Comorbidity Index and Geriatric-8 were not consistently available, data on chemotherapy completion rates and adverse events were incomplete, and molecular information on RAS, BRAF, and microsatellite instability status was lacking for much of the study period. Even so, because the cohort included elderly patients with common comorbidities, it reflects a population closer to real-world practice than the highly selected patients enrolled in clinical trials. The authors conclude that postoperative LMR and CAR are promising predictors of adjuvant chemotherapy efficacy in this growing patient population and hope the work will spur development of novel biomarkers for guiding treatment decisions in elderly cancer care.

Subject of Research: Predicting adjuvant chemotherapy efficacy in elderly stage III colorectal cancer patients using immuno-nutritional and inflammatory blood markers

Article Title: Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer

Article References: Tago, T., Takamizawa, Y., Kato, T., Nagata, H., Moritani, K., Tsukamoto, S., & Kanemitsu, Y. (2026). Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer. Annals of Gastroenterological Surgery, 10(5), 1575-1585. https://doi.org/10.1002/ags3.70235

Image Credits: AI Generated

DOI: 10.1002/ags3.70235

Keywords: colorectal cancer, adjuvant chemotherapy, elderly patients, lymphocyte-to-monocyte ratio, C-reactive protein-to-albumin ratio, immuno-nutritional markers, inflammatory markers, propensity score matching, recurrence-free survival, biomarkers, National Cancer Center Hospital, Annals of Gastroenterological Surgery

The study, led by Ashraf Nadeem, Yunfan Yang, Xinyan Li, and Kun Li of the Department of Hepatobiliary and Pancreatic Surgery at Zhongnan Hospital of Wuhan University, employed a frequentist network meta-analysis, a statistical framework that pools both direct comparisons and indirect evidence across a connected web of randomized trials. Because most adjuvant therapies for liver cancer have been tested only against observation or placebo rather than against each other, conventional pairwise meta-analysis cannot rank them. The network approach uses a shared common comparator—in this case, observation or placebo—as a statistical anchor, allowing the relative performance of treatments that have never faced each other in a trial to be estimated within a single model. Treatments were ranked using P-scores, which express the probability that one intervention outperforms another under the network model.

The evidence base was assembled through an exhaustive search of MEDLINE, Embase, CENTRAL, Web of Science, Scopus, regional databases, clinical trial registries, and conference proceedings covering trials published between January 2000 and December 2025. The investigators deliberately restricted their network to trials conducted exclusively in patients undergoing hepatic resection, excluding mixed populations that also included ablation or transplantation, in order to preserve clinical coherence and strengthen the transitivity assumption on which indirect comparisons depend. The review was prospectively registered in PROSPERO and reported according to the PRISMA 2020 statement and its network meta-analysis extension, with risk of bias assessed using the Cochrane Risk of Bias 2 tool.

The headline finding concerns overall survival. Three internal radiation and brachytherapy approaches dominated the survival hierarchy. Adjuvant iodine-125 brachytherapy showed the largest reduction in the hazard of death compared with observation, with a hazard ratio of 0.36 (95 percent confidence interval 0.17 to 0.78), followed by intensity-modulated radiation therapy, or IMRT, at a hazard ratio of 0.44 (0.23 to 0.86), and iodine-131-labeled metuximab, a radiolabeled antibody targeting HAb18G/CD147 on tumor cells, at 0.46 (0.28 to 0.77). In probabilistic terms, iodine-125 brachytherapy carried the highest P-score for overall survival at 0.86, ahead of IMRT at 0.78 and iodine-131-metuximab at 0.77. Conventional transarterial chemoembolization, long a mainstay of postoperative consolidation, retained activity with a hazard ratio of 0.71 (0.55 to 0.92) but was generally outperformed by the precision radiotherapy approaches.

The picture shifted when the outcome was recurrence-free survival, the primary endpoint of most adjuvant trials and typically the earliest signal of treatment failure. Here, the autologous formalin-fixed tumor vaccine, or AFTV, an immunotherapy prepared from a patient’s own resected tumor tissue, ranked first with a P-score of 0.92, followed by a combination of the traditional medicine Cidan capsule with transarterial chemoembolization at 0.90, iodine-125 brachytherapy at 0.84, and IMRT at 0.80. The divergence between the two hierarchies is not contradictory, the authors argue, but reflects differences in endpoint maturity and mechanism: recurrence events accrue earlier than deaths, and some strategies may suppress relapse long before any difference in survival fully matures.

The mechanistic reasoning behind these rankings is instructive. Early postoperative recurrence in hepatocellular carcinoma is frequently driven by microscopic residual disease, narrow resection margins, microvascular invasion, and venous dissemination—processes that concentrate relapse risk around the surgical bed and regional vascular pathways. IMRT is conceptually well suited to sterilizing this presumed microscopic disease in the postoperative field, whereas transarterial chemoembolization targets hypervascular visible tumor tissue through the arterial supply and is a less precise fit for the minimal residual disease setting. Meanwhile, the immune-based strategies operate systemically. Hepatocellular carcinoma typically arises in a chronically inflamed, immunologically dysregulated liver characterized by T-cell exhaustion and immune escape, and checkpoint inhibition with agents such as the PD-1 inhibitor sintilimab—which demonstrated a favorable benefit-risk profile in the network—aims to restore cytotoxic antitumor immunity against occult malignant clones throughout the remnant liver.

AFTV represents a different immunological logic altogether. Rather than amplifying pre-existing antitumor immunity, the autologous vaccine is designed to generate antigen-specific immune priming de novo, using formalin-fixed tumor tissue as a source of the full repertoire of tumor antigens in each individual patient. The authors note that this strategy is conceptually well matched to the adjuvant setting, where disease burden is minimal and immune containment is more achievable than in advanced disease. They are careful, however, to frame the finding as hypothesis-generating rather than definitive: the AFTV ranking rests on a single small phase II trial, mature overall survival data are lacking, and personalized vaccine platforms face practical challenges around standardization, scalability, and reproducibility across centers.

Safety signals across the 28 trials were reassuring. Grade 3 or higher adverse events were reported infrequently. Immune-related hepatitis of grade 3 occurred in 2 to 5 percent of patients receiving sintilimab, with no treatment-related deaths. Radiation-induced liver disease of grade 3 or worse was rare, affecting fewer than 1 percent of Child-Pugh A patients treated with IMRT. Post-embolization syndrome affected 5 to 10 percent of patients undergoing transarterial chemoembolization, and no grade 3 or higher events were reported for AFTV. The analysis also revealed that the strongest efficacy signals frequently came from clinically enriched high-risk populations: the sintilimab trial enrolled a cohort with 100 percent pathological microvascular invasion, the IMRT trial enrolled patients with 100 percent portal vein tumor thrombus, and the AFTV trial arose from a population with very high hepatitis B prevalence—features that matter for generalizability, since most included patients had hepatitis B virus-related disease and preserved liver function.

The authors are candid about the limitations of their work. The evidence network was largely star-shaped, with observation as the dominant comparator, meaning most comparisons between active treatments were estimated indirectly. Because the network contained no closed loops, formal consistency testing was not possible, and coherence rests entirely on the transitivity assumption. Hepatitis B prevalence ranged from 36 to 100 percent and microvascular invasion rates from 0 to 100 percent across trials, and meta-regression was infeasible given the small number of trials per covariate category. Landmark mixed-modality trials such as IMbrave050, which showed that adjuvant atezolizumab plus bevacizumab can reduce recurrence risk in high-risk patients after resection or ablation, could not be included because resection-specific estimates were not extractable. Evolving salvage therapies over the 26-year study window may also have influenced survival endpoints in older trials.

Nevertheless, the analysis points toward a future in which postoperative management of liver cancer is risk-adapted and mechanism-based rather than empiric. Precision radiotherapy may be most rational when relapse risk is concentrated in the surgical bed or vascular territory, while immune-based therapy may better serve patients whose recurrence risk is diffuse or systemic. The authors emphasize that not every patient should automatically receive adjuvant treatment; the strongest case exists for those with clearly elevated risk, such as microvascular invasion or tumor multiplicity. Large active-comparator randomized trials, standardized treatment-initiation windows, and biomarker-informed selection will be needed before a definitive standard emerges. Until then, this synthesis provides the clearest comparative map yet of a therapeutic landscape long defined by uncertainty.

Subject of Research: Comparative effectiveness of postoperative adjuvant therapies for hepatocellular carcinoma after curative resection, evaluated by network meta-analysis of randomized controlled trials

Article Title: Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysis

Article References: Nadeem, A., Yang, Y., Li, X., & Li, K. (2026). Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysis. Clinical Cancer Bulletin, 5(1), Article 14. https://doi.org/10.1007/s44272-026-00066-2

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00066-2

Keywords: hepatocellular carcinoma, network meta-analysis, adjuvant therapy, liver resection, iodine-125 brachytherapy, IMRT, iodine-131 metuximab, recurrence-free survival, overall survival, immunotherapy, tumor vaccine, TACE